nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2010-90nnp-46Research ArticlePHARMACOTHERAPYФАРМАКОТЕРАПИЯSymptom modifiers in therapy for ankylosing spondylitisАнкилозирующий спондилит и симптом-модифицирующие препараты в его терапииБадокинВ. В.BadokinV. V.

Москва

Moscow

vbadokin@yandex.ruРоссийская медицинская академия последипломного образованияРоссияRussian Medical Academy for Postgraduate EducationRussian Federation20101306201022NO2 (2010)7782Copyright © Badokin V.V., 20102010Бадокин В.В.Badokin V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/46

Based on the data available in the literature, the author gives information on the prevalence of ankylosing spondyloarthritis. The clinical picture and pathogenesis of this disease and the principles of its diagnosis and treatment are described. Particular emphasis is placed on the use of etoricoxib, a nonsteroidal anti-inflammatory drug, in ankylosing spondyloarthritis. The available data strongly prove that etoricoxib is an alternative in the treatment of inflammatory diseases of the joints and vertebral column, ankylosing spondyloarthritis in particular.

Приведены данные о распространенности анкилозирующего спондилоартрита. Описаны клиническая картина и патогенез заболевания, принципы его диагностики и лечения. Особое внимание уделено использованию при анкилозирующем спондилоартрите эторикоксиба, относящегося к нестероидным противовоспалительным препаратам. Имеющиеся данные убедительно доказывают, что эторикоксиб является альтернативой в лечении воспалительных заболеваний суставов и позвоночника, в частности анкилозирующего спондилоартрита.

анкилозирующий спондилоартритсимптом-модифицирующая терапияглюкокортикоидыэторикоксибankylosing spondyloarthritissymptom-modifying therapynonsteroidal anti-inflammatory drugsglucocorticoidsetoricoxibReferences<div><p>Braun J., Bollow M., Remlinger G. et al. Prevalence of spondylarthropathies in HLA- B27-positive and -negative blood donors. Arhr Rheum 1998; 41: 58-67.</p><p>Ward D.D. Health related quality in ankylosing spondylitis: a survey of 175 patients. Arthr Care Res 1999; 12: 247-55.</p><p>Gran О.Т., Skomvoll J.F. The outcome of ankilosing spondylitis: a study of 100 patients. Br J Rheumatol 1997; 36(7): 766-71.</p><p>McGonagle D., Khan M.A., Mazzo-Ortega H. et al. Enthesitis in spondyloarthritis. Curr Opin Rheumatol 1999; 11(4): 244-50.</p><p>Dougados M., Dijrmans B., Khan M. et al. Сonventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002; 61(Suppl. III): 40-50.</p><p>Алексеев В.В. Диагностика и лечение болей в спине. Соnsilium medicum 2002; 4(2): 96-102.</p><p>Chen D.-F., Bianchetti M., Weisendanger M. Motor disturbances. R Benecke et al. (eds). L., 1987.</p><p>Amor B. Data management in spondylarthropathies. Rheumatol Eur 1996; 25(3): 92-5.</p><p>Wanders A., Heijde D., Landewе R. et al. Non-steroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthr Rheum 2005; 52(6): 1756-65.</p><p>Dougados M., Revel M., Khan M. Spondyloarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillaries Clin Rheumatol 1998; 12: 717-36.</p><p>Friesen R.W., Brideau C., Chan C.C. et al. 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 1998; 8(19): 2777-82.</p><p>Инструкция по медицинскому применению препарата Аркоксиа (эторикоксиб), 2008. http://www.vidal.ru/poisk_preparatov/arcox-ia.htm.</p><p>Greenwald M., Peloso P., Hasler F. et al. Etoricoxib improves pain and function in rheumatoid arthritis patients on background biologic therapy. Arthr Rheum 2009; 60(10, Suppl.): 606-13</p><p>Van der Heijde D., Baraf H.S., Ramos-Remus C. et al. Evalution of the efficacy of etorycoxib in ankylosing spondylitis. Results of a fifty-two-week, randomized, controlled study. Arthr Rheum 2005; 52: 1205-16.</p><p>Hunt R.H., Harper S., Watson D.J. et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98: 725-33.</p><p>Ramey D.R., Watson D.J., Yu C. et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib versus. nonselective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005; 21: 715-22.</p><p>Watson D.J., Bolognese J.A., Yu C. et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin 2004; 20: 1899-908.</p></div><br /><div><p>Braun J., Bollow M., Remlinger G. et al. Prevalence of spondylarthropathies in HLA- B27-positive and -negative blood donors. Arhr Rheum 1998; 41: 58-67.</p><p>Ward D.D. Health related quality in ankylosing spondylitis: a survey of 175 patients. Arthr Care Res 1999; 12: 247-55.</p><p>Gran О.Т., Skomvoll J.F. The outcome of ankilosing spondylitis: a study of 100 patients. Br J Rheumatol 1997; 36(7): 766-71.</p><p>McGonagle D., Khan M.A., Mazzo-Ortega H. et al. Enthesitis in spondyloarthritis. Curr Opin Rheumatol 1999; 11(4): 244-50.</p><p>Dougados M., Dijrmans B., Khan M. et al. Сonventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002; 61(Suppl. III): 40-50.</p><p>Алексеев В.В. Диагностика и лечение болей в спине. Соnsilium medicum 2002; 4(2): 96-102.</p><p>Chen D.-F., Bianchetti M., Weisendanger M. Motor disturbances. R Benecke et al. (eds). L., 1987.</p><p>Amor B. Data management in spondylarthropathies. Rheumatol Eur 1996; 25(3): 92-5.</p><p>Wanders A., Heijde D., Landewе R. et al. Non-steroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthr Rheum 2005; 52(6): 1756-65.</p><p>Dougados M., Revel M., Khan M. Spondyloarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillaries Clin Rheumatol 1998; 12: 717-36.</p><p>Friesen R.W., Brideau C., Chan C.C. et al. 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 1998; 8(19): 2777-82.</p><p>Инструкция по медицинскому применению препарата Аркоксиа (эторикоксиб), 2008. http://www.vidal.ru/poisk_preparatov/arcox-ia.htm.</p><p>Greenwald M., Peloso P., Hasler F. et al. Etoricoxib improves pain and function in rheumatoid arthritis patients on background biologic therapy. Arthr Rheum 2009; 60(10, Suppl.): 606-13</p><p>Van der Heijde D., Baraf H.S., Ramos-Remus C. et al. Evalution of the efficacy of etorycoxib in ankylosing spondylitis. Results of a fifty-two-week, randomized, controlled study. Arthr Rheum 2005; 52: 1205-16.</p><p>Hunt R.H., Harper S., Watson D.J. et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98: 725-33.</p><p>Ramey D.R., Watson D.J., Yu C. et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib versus. nonselective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005; 21: 715-22.</p><p>Watson D.J., Bolognese J.A., Yu C. et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin 2004; 20: 1899-908.</p></div><br />

The authors declare that there are no conflicts of interest present.